Genentech Growth Study Program

Genentech National Cooperative Growth Study Surveillance Program for Nutropin, Nutropin AQ and Protropin

Protocol Description

This is a multicenter observational study to gather information about specific aspects of growth hormone replacement therapy using recombinant DNA growth hormone from Genentech. The primary objective of this long-term study is to collect safety and efficacy information regarding use of these therapies in treatment of children who have growth failure due to lack of adequate endogenous growth hormone secretion, short stature due to chronic renal insufficiency and Turner Syndrome.

Eligibility Criteria

Children of either sex up to age 17 who are being treated with Genentech’s Nutropin®, Nutropin AQ or Protropin® for growth failure are eligible to participate, subject to certain exclusions.
Boys: All ages
Girls: All ages


Participation will only involve data collection, starting during each participant’s first treatment with growth hormone, and will continue during subsequent routine visits with the child’s doctor. The study will collect and record all medical record information from lab tests, x-rays and clinic visits.
Visits: None beyond normal clinical care
Duration: Until patient is no longer seen in clinic

Status: Open for Enrollment

Source(s) of Support

Genentech, Inc.

Primary Investigator

Oscar Escobar, MD

Contact Information

To get started, pleasse contact:
Ana Diaz, RN
Virginia Stefanick, RN